Crystalline Form of Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoicacid] Calcium Salt
AssigneeAstraZeneca UK Limited
InventorsRebecca Jane Booth, Peter Anthony Cittern, Jeffrey Norman Crabb, John Horbury, David Wyn Calvert Jones
Life of this patent
Estimating the term…
Abstract
Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.
Claims20
A crystalline hydrated form of the compound bis[(E)-7-[4-(4fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt of formula I
- having an X-ray powder diffraction pattern with peaks at 2-theta (2θ)=8.8, 13.1 and 21.5°.
A crystalline form of the compound bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt of formula I
- having an X-ray powder diffraction pattern with peaks at 2-theta (2θ)=4.4, 7.7, 9.0 and 20.7°.
13-15. (canceled)
(canceled)
Dependencies are inferred from the claim text.